Doctors hail new front in cancer fight

Treatments turn the body into a weapon against tumours

Novel cancer drugs tipped to boost drug sales

Immunotherapy moves out of clinical trials into real world use

Cellectis in takeover talks with Pfizer

US pharma company makes approach worth as much as €1.5bn

Teva pays $1.2bn in antitrust drugs case

Record FTC settlement highlights pressure from generic rivals

Aircraft landing on runway
©Photographers Choice/Getty

Movie’s theme: does flying poison you?

Former pilot’s film about airline cabin air quality

Cinven to buy Labco in €1.2bn deal

Move comes after French medical group abandoned float plans

The startling rise in short-sightedness

Cases of myopia have doubled in Europe

Pfizer-AstraZeneca — deal that never was

How pharma groups are faring after thwarted merger

©James Ferguson

French group trumpets Cuba pharma

Abivax plans IPO to fund Havana-developed hepatitis treatment

DNA double helix. High resolution 3d rendering.

Boston health tech group seeks London IPO

PureTech’s float comes amid UK’s growing life science investment

P&G gets skin in 3D bioprinting game

Consumer goods maker explores printing of living human tissue

Care UK in talks to sell division to Mears

Group seeks to add more residential care homes for elderly

GSK chief given time to restore growth

Shareholders warn that growth must ‘revive by next year’

Small-cap Week, May 23

Tungsten, Zytronic, Quantum Pharma and Mar City featured

Reckitt faces regulatory friction on K-Y

UK watchdog raises concern over impact on competition

Hikma founder Samih Darwazah dies at 85

Palestinian who built Hikma into Arab world’s biggest drugmaker

Penthouse gym to cater for high-flyers

Fitness First opens invitation-only Singapore facility to bring workouts to wealthy

Circassia deal signals UK biotech revival

Share placement shows fresh appetite for life-science drug groups

Endo/Par: too much of a good thing

Group has rebuilt itself with deals but the latest is a big bite

Endo to buy Par in $8bn deal

Buyout group has roughly quintupled its $1.9bn investment in US drugmaker


More FT Twitter accounts